INIS
antibodies
100%
covid-19
45%
comparative evaluations
44%
patients
43%
vaccines
34%
antigens
32%
viruses
29%
evaluation
27%
detection
24%
messenger-rna
20%
doses
20%
performance
19%
administration
19%
sensitivity
19%
women
17%
immunity
16%
workers
15%
control
15%
levels
14%
capacity
14%
proteins
14%
values
13%
neutrophils
11%
populations
10%
kinetics
10%
specificity
10%
diseases
8%
blood
8%
data
7%
symptoms
7%
dynamics
7%
pregnancy
7%
receptors
7%
elisa
7%
strains
7%
computerized tomography
7%
peaks
6%
geometry
6%
polymerase chain reaction
6%
thrombosis
6%
neonates
6%
assessments
6%
lungs
6%
influenza
6%
biological markers
6%
nucleosomes
6%
durability
6%
transplants
6%
correlations
6%
pcr
5%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
65%
Neutralizing Antibody
61%
Omicron Coronavirus Variant
31%
Monospecific Antibody
25%
Binding Antibody
21%
Vaccine Efficacy
18%
Antibody Response
18%
COVID-19
16%
Humoral Immunity
16%
Virus Neutralization
16%
Vaccination Policy
15%
Immunoglobulin G Antibody
12%
Titer
12%
Neutralization
12%
Immunogenicity
12%
Breakthrough Infection
9%
Spike
8%
Viral Load
7%
Serology
7%
Respiratory Syncytial Virus
6%
Influenza
6%
Adoptive Immunity
6%
ELISA
6%
Lung Transplantation
6%
Dynamics
6%
Receptor Binding
5%
Immunoassay
5%
Keyphrases
Bivalent Boosters
12%
Breakthrough Infection
8%
XBB.1.5
8%
Subvariant
7%
SARS-CoV-2 Omicron
6%
Clinical Performance Evaluation
6%
Rapid Antigen
6%
Pseudotyped Virus
6%
SARS-CoV-2 Neutralizing Antibody
6%
Breakthrough Cases
6%
Moderna mRNA-1273
6%
SARS-CoV-2 IgG Antibody
6%
Antigen Test
6%
SARS-CoV-2 Surrogate
6%
Analytical Sensitivity
6%
SARS-CoV-2 Antigen
6%
Delta Variant
6%
ChAdOx1 nCoV-19
6%
NETosis
6%
COVID-19 Breakthrough Infections
6%
N Antigen
6%
Analytical Kits
6%
Positivity Rate
6%
Anti-SARS-CoV-2 Antibodies
6%
Neutralizing Antibodies
6%
BNT162b2
6%
AZD7442
6%
Cilgavimab
6%
Tixagevimab
6%
Omicron Sub-lineages
6%
Geometric Mean Titer
5%
